Infinitopes Adds Biotech Veterans to Board Amid Clinical Expansion

Infinitopes, a precision immuno-oncology company, has announced the appointment of Dan Menichella and Dr. Jo Brewer as Non-Executive Directors as it transitions into a clinical-stage company with its lead vaccine candidate, ITOP1, targeting oesophageal cancer. The appointments mark a strategic step in advancing next-generation cancer vaccines.

Dan Menichella brings deep expertise in biotech leadership, having driven high-value partnerships and strategic deals at CureVac and Bamboo Therapeutics. His track record includes securing billion-dollar collaborations with industry leaders like Eli Lilly, Biogen, and Takeda. With experience in fundraising, M&A, and corporate growth, Menichella is poised to help steer Infinitopes’ expansion and clinical progress.